Earlier this month, a startling corporate announcement from pharmaceutical giant Novartis sent massive ripples through the global cardiovascular medicine community.

The HORIZON study—a massive seven-year phase three clinical trial tracking 8,323 participants—was designed to deliver conclusive proof that reducing levels of the lipoprotein(a) protein could actively prevent strokes and heart attacks. Instead, heart specialists worldwide were stunned to learn the trial failed its primary endpoint. While the experimental drug successfully suppressed Lp(a) levels, it shockingly failed to lower cardiovascular event rates when stacked against a placebo.

“It’s a bit of a shock,” notes Riyaz Patel, professor of preventive cardiology at University College London. “There’s lots of people out there who are confused right now, because in the last five years, everyone from cardiologists to influencers has been banging on about the importance of Lp(a).”

The History and Genetics of a Diabolical Molecule

To grasp the gravity of this development, one must look back to the early 1960s when a Norwegian geneticist first identified that Lp(a) might drive a distinct subset of cardiovascular cases. Decades of subsequent research have consistently linked elevated concentrations of this cholesterol-carrying particle to heart disease. For instance, a longitudinal study tracking 6,238 adults aged 43 to 65 over an average of nine years found that high Lp(a) levels tripled the risk of suffering a heart attack. Genetic investigations have repeatedly flagged the marker as a prominent risk factor.

While the exact molecular pathways tying Lp(a) to heart disease remain under investigation, researchers have linked elevated levels to proinflammatory triggers, blood clot formation, narrowing of the aortic valve, and dangerous arterial plaque accumulation.

“It’s become known that Lp(a) is not just simply associated with cardiovascular disease, but the higher the level, the worse the outcomes,” explains Robert Block, professor of internal medicine and preventive cardiology at the University of Rochester Medical Center.

Unlike standard risk factors like LDL cholesterol—which fluctuate based on diet and physical activity—a person’s baseline Lp(a) is dictated almost entirely by genetics. Because roughly 20% to 30% of the global population carries elevated levels, it earned the frightening moniker of the diabolical molecule.

The Race for Treatments Meets a Roadblock

This genetic certainty sparked a gold rush for biotech therapies and pushed organizations like the American Heart Association to recommend that every adult undergo lifetime Lp(a) screening. Developers rushed to create targeted therapies, including antisense oligonucleotides like Novartis's pelacarsen—which lowers Lp(a) production by up to 80%—and gene-silencing small interfering RNAs (siRNAs).

The medical community anticipated that HORIZON would inaugurate a new era of preventive cardiology. Instead, the setback has thrust researchers into uncharted territory.

“Now we’re in this limbo zone where we think Lp(a) is a problem if it’s high, but lowering it doesn’t seem to make a difference, at least from this one trial,” Patel states.

Looking Ahead: More Trials on the Horizon

Comprehensive data from the HORIZON study is slated for release in November at the AHA annual meeting. Meanwhile, experts warn against prematurely dismissing the target. Block points to past data from the LDL-lowering injection Repatha, which showed even stronger risk reductions among patients with concurrent high Lp(a) levels.

Furthermore, trial design nuances may explain the outcome. Michael Shapiro, professor of cardiology and molecular medicine at Wake Forest University, highlights that trial participants were already utilizing statins and hypertension medications to control standard risk factors.

Additional late-stage trials from Amgen, Eli Lilly, and others are currently evaluating alternative siRNA formulations and oral small molecules like muvalaplin. Only time, complete trial data sets, and upcoming readouts will reveal whether targeting Lp(a) remains a viable medical strategy or requires a fundamental overhaul of modern drug discovery.